Longevity Scientist: Aging Is A Disease. We Just Don’t Know How to Treat (yet). Beyond Tomorrow Podcast (opens in new tab)

The interview features Joe Betts-LaCroix, CEO and co-founder of Retro Biosciences, detailing the company’s objective to extend healthy human lifespan by ten years using a targeted, multi-platform biotechnology approach. Capitalized by a single $180 million angel investment from OpenAI’s Sam Altman, Retro Biosciences prioritizes translating aging biology into clinical therapeutics while rejecting the hyper-speculative timelines common in the longevity sector. The structural foundation of moder...